**Review Article**

**Epigenetic Regulation of Hepatocellular Carcinoma Progression through the mTOR Signaling Pathway**

Mengnan Guo, Ning Li, Jianxia Zheng, Wei Wang, Yan Wu, Xu Han, Jiapei Guo, Weixi Chen, Zekun Bai, Wen Bai, and Jinghua Wu

1 Tangshan Maternal and Child Health Care Hospital, North China University of Science and Technology, Tangshan 063000, Hebei, China
2 North China University of Science and Technology Affiliated Hospital, Tangshan 063000, Hebei, China

Correspondence should be addressed to Jinghua Wu; tswujinghua@163.com

Received 21 February 2021; Accepted 11 May 2021; Published 25 May 2021

Academic Editor: José L. Mauriz

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is an aggressive tumor with a high mortality rate because of the limited systemic and locoregional treatment modalities. The development and progression of HCC depend on epigenetic changes that result in the activation or inhibition of some signaling pathways. The mTOR signaling pathway is essential for many pathophysiological processes and is considered a major regulator of cancer. Increasing evidence has shown that epigenetics plays a key role in HCC biology by regulating the mTOR signaling pathway. Therefore, epigenetic regulation through the mTOR signaling pathway to diagnose and treat HCC will become a very promising strategy.

**1. Introduction**

Hepatocellular carcinoma (HCC) is the fifth most common malignancy in men and the seventh most common malignancy in women worldwide and results in more than 700,000 deaths each year [1–3]. Further deterioration of HCC can be prompted by failure of early diagnosis, lack of effective therapeutic targets, and inadequate surveillance. Therefore, the development of novel diagnostic methods and the identification of novel targets for therapeutic intervention are urgently needed for the diagnosis and treatment of HCC [4].

Epigenetics is a heritable phenomenon that affects gene expression without altering the DNA sequence [5]. Epigenetics has been found to regulate gene expression mainly through four mechanisms: DNA methylation, histone modification, chromatin remodeling, and noncoding RNA regulation [6, 7]. Aberrant epigenetic regulation plays an important role in the development of human malignancies, including HCC. Therefore, better understanding of the abnormal epigenetic regulations in HCC may provide new options for the diagnosis and treatment of HCC. In addition, epigenetics also regulates signaling pathways such as the NF-κB, RAF/MEK/ERK, JAK-STAT, Wnt, Notch, and MAPK as well as mTOR pathways [8–10]. Moreover, alterations in these signaling pathways can lead to changes in the biological traits of HCC cells to some extent [11]. Among these signaling pathways, the mTOR signaling pathway plays an important role in affecting HCC progression.

mTOR is involved in multiple signaling pathways that regulate cell proliferation, autophagy, and apoptosis in vivo [12]. There are two main mTOR signaling pathways: the classical PI3K/Akt/mTOR signaling pathway and the LKB1/AMPK/mTOR signaling pathway. Mutation, activation, and silencing of mTOR upstream genes, thereby regulating the mTOR pathway, affect the development process of HCC [7]. In addition, mTOR can also regulate protein synthesis by phosphorylating downstream target proteins p70s6k kinase (e.g., 6K1 and 4EBP1), which then regulate mRNA translation [13]. Therefore, changes in upstream and downstream genes of mTOR leading to dysregulation of mTOR signaling pathway will affect the progression of HCC. More than 70%
of cancers are known to result in hyperactivation of mTOR. mTOR inhibitors have thus been widely studied for their use in cancer treatment, and some of these inhibitors (e.g., rapamycin, everolimus, doxorubicin, and sorafenib) are used for the treatment of HCC. However, clinical studies have shown that mTOR inhibitors have some limitations, such as low bioavailability and toxicity, and some cancers eventually acquire drug resistance [14–16]. Based on the limited efficacy of mTOR inhibitors, other novel drugs targeting mTOR need to be identified. Several mTOR inhibitors are currently under investigation for the treatment of HCC, and although many preclinical and clinical trial studies have been conducted, these inhibitors have not been applied. Therefore, the discovery of novel regulators of mTOR may become a new therapeutic target for HCC.

In a review, we systematically summarize information regarding the regulation of the mTOR signaling pathway by factors mutated in epigenetic inheritance for the diagnosis and treatment of HCC (Figure 1).

2. ncRNAs
Noncoding RNA (ncRNA) refers to RNA that does not encode proteins [17]. Advances in sequencing technologies have led to the discovery of many ncRNA species, some of which are highly conserved, such as microRNAs (miRNAs), ultraconserved regions of transcription [18] and circRNAs (circRNAs), as well as ncRNAs that are not conserved between other species, such as long noncoding RNAs (lncRNAs) [19]. Studies have demonstrated that ncRNAs regulate cellular processes and pathways in developmental and pathological contexts [20]. In human diseases, particularly cancer, deregulated expression of ncRNAs can lead to changes in signaling pathways that can affect tumor development. Research has shown that ncRNAs are key players in human carcinogenesis and therefore may play potential roles in the diagnosis and treatment of cancer.

2.1. MiRNAs and HCC. MiRNAs are a diverse family of highly conserved ncRNAs with sizes that range from approximately 18 to 25 nucleotides. MiRNAs pair by complete or incomplete base complementation with the 3’ untranslated region of mRNA. This pairing leads to the degradation or inhibition of the target mRNA, with subsequent effects on protein expression. MiRNAs participate in the processes of cell growth, differentiation, development, proliferation, apoptosis, and metabolism [21, 22]. MiRNAs also play an important role in the physiological and pathological processes of cancer, including HCC. In recent years, a large number of studies have shown that the expression levels of miRNAs in HCC are upregulated or downregulated to varying degrees, suggesting that they play a role in various biological processes such as growth, proliferation, and apoptosis of HCC cells [23–26]. Therefore, miRNAs are very promising targets in the diagnosis and treatment of HCC.

2.1.1. MiRNA Regulation of the PI3K/AKT/mTOR Signaling Pathway in HCC. HCC is the third leading cause of cancer-related death worldwide, and its incidence continues to rise. Although cirrhosis underlies most cases of HCC, many molecular pathways are closely associated with HCC carcinogenesis [27]. For example, activation or upregulation of the PI3K/AKT/mTOR signaling pathway can affect the occurrence and development of tumors [28]. The deregulation of this pathway has been shown to result from the deregulation of miRNAs. In HCC induced by mTOR signaling, the expressions of some miRNAs are decreased, and upregulation of these miRNAs is required to inhibit HCC development, while some miRNAs are increased in HCC (Table 1). A total of sixteen miRNAs (miR-1914 [29], miR-192-5p [30], miR-486-5p [31], miR-601 [32], miR-132 [33], miR-1207-5p [34], miRNA-133b [35], miR-144-3p [36], miR-26a [37], miR-21 [38], miR-199a-3p [39, 40], miR-758-3p [41], miR-494 [42], miR-125a [43], miR-345 [44], and miR-29a-3p [45]) have been identified as downregulated in HCC. Three miRNAs (miR-9-5p [46], miR-300 [47], and miR-181a [48]) were identified as upregulated in HCC.

2.1.2. MiRNA Regulation of Other mTOR Signaling Pathways in HCC. In addition to miRNA-mediated regulation of the classical PI3K/AKT/mTOR signaling pathway, miRNAs can also affect HCC development through other mTOR signaling pathways.

In HCC, upregulation of miR-18a and miR-25 is associated with poor patient survival and promotion of HCC cell line proliferation. Sanchez-Mejias et al. [49] analyzed the predicted targets of some miRNAs and validated SOCS5 as a bona fide target of miR-18a and miR-25. Furthermore, the authors demonstrated that the SOCS5/miR-18a/miR-25 axis inhibits HCC development by regulating downstream mTOR signaling.

Zhou et al. [50] found that miR-100 downregulation was closely related to the development of HC. MiR-100 reduces the protein level of angiotropin 2 (Angpt2) by targeting mTOR and blocking the mTOR-p70S6K signaling pathway, which in turn inhibits the formation of encapsulated tumor clusters (VETC), thereby eliminating VETC-dependent metastasis of HCC cells. These results indicate miR-100 as a new target for antimetastatic therapy of HCC.

Meanwhile, the experimental results of Dong et al. [51] showed that miR-223 could inhibit cell growth and promote apoptosis in HepG2 and Bel-7402 hepatoma cell lines and screened a novel miR-223 target, the Ras-related protein Rab-1 (Rab1). MiR-223 mediates mTOR signaling pathway inactivation by targeting Rab1, thereby inhibiting tumorogenesis and promoting HCC apoptosis. Therefore, miR-223 could be a potential therapeutic target for the treatment of HCC.

These studies indicate miRNAs can affect the progression of liver cancer by regulating the mTOR signaling pathway and provide a new approach for the diagnosis and treatment of liver cancer.

2.2. LncRNAs and HCC. Among the various types of ncRNAs, lncRNAs have received increasing attention. LncRNAs are defined as transcripts of more than 200
nucleotides that lack protein-encoding ability [52]. LncRNAs regulate the expression of genes by epigenetic regulation, transcriptional regulation, and posttranscriptional regulation in the form of RNA [53]. Therefore, LncRNAs have been shown to function as master regulators of gene expression and can play critical roles in various biological functions and disease processes in cancer, including HCC [54]. The genome-wide expression pattern of LncRNAs in HCC cells or tissues and their tissue-specific expression characteristics have been found by a number of studies, and LncRNAs hold promise as novel diagnostic biomarkers and therapeutic targets for HCC [55].

2.2.1. LncRNAs Regulate the PI3K/Akt/mTOR Signaling Pathway in HCC. With the development of next-generation sequencing, more long noncoding RNAs (LncRNAs) were found. Initially, IncRNAs were considered as “noisy” transcripts or “dark matter” [56]. An increasing number of studies have revealed the indispensable role of IncRNAs in the dysregulation of signaling pathways in HCC [57]. The impact of IncRNAs on the progression of HCC through the PI3K/Akt/mTOR signaling pathway is relatively novel. Upregulation or downregulation of PI3K/AKT/mTOR-related oncogenic IncRNAs contributes to aberrant expression of transcriptional activators or oncoproteins, leading to aberrant regulation of the PI3K/AKT/mTOR pathway in HCC [58]. In addition, IncRNAs are aberrantly expressed in liver cancer and are significantly associated with metastasis, recurrence, prognosis, and chemoresistance of HCC [59]. Here, we summarize that 13 IncRNAs are dysregulated in HCC through the PI3K/Akt/mTOR signaling pathway.

### Table 1: Dysregulated miRNAs in HCC.

<table>
<thead>
<tr>
<th>MiRNAs</th>
<th>Target</th>
<th>Expression</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>MiR-1914</td>
<td>GPR39</td>
<td>Downregulated</td>
<td>[29]</td>
</tr>
<tr>
<td>MiR-192-5p</td>
<td>TRIP13</td>
<td>Downregulated</td>
<td>[30]</td>
</tr>
<tr>
<td>MiR-486-5p</td>
<td>IGF-1R</td>
<td>Downregulated</td>
<td>[31]</td>
</tr>
<tr>
<td>MiR-601, miR-132</td>
<td>PIK3R3</td>
<td>Downregulated</td>
<td>[32, 33]</td>
</tr>
<tr>
<td>MiR-1207-5p</td>
<td>FASN</td>
<td>Downregulated</td>
<td>[34]</td>
</tr>
<tr>
<td>MiR-133b</td>
<td>EGFR</td>
<td>Downregulated</td>
<td>[35]</td>
</tr>
<tr>
<td>MiR-144-3p</td>
<td>SGK3</td>
<td>Downregulated</td>
<td>[36]</td>
</tr>
<tr>
<td>MiR-26a</td>
<td>ST3GAL</td>
<td>Downregulated</td>
<td>[37]</td>
</tr>
<tr>
<td>MiR-21</td>
<td>PTEN</td>
<td>Downregulated</td>
<td>[38]</td>
</tr>
<tr>
<td>MiR-199a-3p</td>
<td>mTOR pathway</td>
<td>Downregulated</td>
<td>[39, 40]</td>
</tr>
<tr>
<td>MiR-758-3p</td>
<td>mTOR pathway</td>
<td>Downregulated</td>
<td>[41]</td>
</tr>
<tr>
<td>MiR-494</td>
<td>mTOR pathway</td>
<td>Downregulated</td>
<td>[42]</td>
</tr>
<tr>
<td>MiR-125a</td>
<td>mTOR pathway</td>
<td>Downregulated</td>
<td>[43]</td>
</tr>
<tr>
<td>MiR-345</td>
<td>IRF1</td>
<td>Downregulated</td>
<td>[44]</td>
</tr>
<tr>
<td>MiR-29a-3p</td>
<td>Robo1</td>
<td>Downregulated</td>
<td>[45]</td>
</tr>
<tr>
<td>MiR-9-5p</td>
<td>KLF4</td>
<td>Upregulated</td>
<td>[46]</td>
</tr>
<tr>
<td>MiR-300</td>
<td>FOXO1</td>
<td>Upregulated</td>
<td>[47]</td>
</tr>
<tr>
<td>MiR-181a</td>
<td>PTEN</td>
<td>Upregulated</td>
<td>[48]</td>
</tr>
</tbody>
</table>

### Figure 1: Epigenetic regulation of the mTOR signaling pathway in HCC.
Several studies have shown that lncRNAs also regulate other mTOR signaling pathways in liver cancer. M& colleagues [74] found that abnormal expression of the lncRNA HEIH was associated with HCC cell growth and metastasis. HEIH was highly expressed in tumor tissue, and HEIH reduction significantly reduced Huh7 and Hep3B hepatoma cell viability, migration, and invasion and induced apoptosis. MiR-199a-3p was identified as a downstream effector of HEIH, and the functional effects of HEIH on Huh7 and Hep3B cells were attenuated when the miR-199a-3p expression was inhibited. In addition, reduced HEIH inhibited the activation of mTOR signaling by upregulating miR-199a-3p, indicating that HEIH may be a potential target for HCC.

Wei and colleagues [75] found significantly increased HOTAIR expression in 84 HCC tissues compared with nontumor tissues and determined the effect of HOTAIR on HCC cell-regulated glucose metabolism by examining lactate and glucose levels. The authors found that HOTAIR promotes glycolysis by upregulating glucose transporter isoform 1 (GLUT1) and activating mTOR signaling, while downregulation of HOTAIR inhibits this effect. This study revealed a new relationship between HOTAIR and glucose metabolism in HCC cells and indicated HOTAIR as a new target for the diagnosis and treatment of HCC.

Li et al. [76] found for the first time the upregulation of lncRNA-OR3A4 in HCC tissues and cell lines and identified OR3A4 as a promoter of HCC progression and angiogenesis. OR3A4 regulates HCC proliferation, metastasis, and angiogenesis through AGGF1/AKT/mTOR. The authors revealed that OR3A4 is a novel predicted target for HCC.

The lncRNA HIF1A-AS1 is overexpressed in HCC tissues and is associated with tumor size, TNM stage, and lymph node metastasis. Hong et al. [77] found that HIF1A-AS1 promotes hepatocarcinogenesis by activating autophagy through the HIF-1α/mTOR signaling pathway. The authors showed that HIF1A-AS1 is involved in regulating the progression of HCC and provided a potential direction for future HCC treatment strategies.

These reports indicate that dysregulation of lncRNAs can activate the mTOR signaling pathway to regulate the development of HCC, taking the understanding and potential use of lncRNAs in the diagnosis and treatment of liver cancer patients to a new level.

2.3. CircRNAs Modulate the mTOR Signaling Pathway in HCC. CircRNAs can affect the development and progression of HCC through the mTOR signaling pathway [86]. For example, Huang et al. [87] showed that circRNA-100338 activation of the mTOR signaling pathway through the circRNA-100338/miR-141-3p/RHEB axis is closely related to the poor prognosis of hepatitis B-related HCC. This study makes the connection between circRNA-100338 and mTOR signaling pathway in HCC cells and may provide a potential therapeutic target for HCC.

Sun et al. [88] found that three circRNAs—circRNA0004001, circRNA 0004123, and circRNA0075792—were upregulated in HCC blood samples using qRT-PCR. The expression of the three circRNAs was positively correlated with TNM stage and tumor size, and the three circRNA combination targeted a variety of miRNAs to participate in the mTOR signaling pathway, correlated with the development of liver cancer, and may be valuable diagnostic biomarker for HCC.

Zheng et al. [89] found that hsa-circ-0079929 was expressed at low levels in HCC. CircRNA-0079299 overexpression inhibited HCC growth and delayed cell cycle progression in vitro and in vivo but had no effect on cell migration and apoptosis. The inhibition of HCC growth by circRNA-0079299 is mediated by the PI3K/AKT/mTOR signaling pathway.

Although few reports have shown that circRNAs play a role in HCC through the mTOR signaling pathway, future studies clarifying their role in HCC development may lead to new approaches for the diagnosis and treatment of HCC.

3. DNA Methylation

DNA methylation is an important epigenetic modification that occurs mainly at the CpG islands of DNA and involves either hypermethylation or hypomethylation. Aberrant
DNA methylation in cancer has been heralded as a promising target for the development of powerful diagnostic, prognostic, and predictive biomarkers [90]. For example, Abeni et al. [10] found that oncogene hypermethylation led to activation of mTOR signaling and inhibited tumor progression after sorafenib treatment. In addition, Liu et al. [91] found that the BCLB gene is methylated in HCC. Hypermethylated BCLB, which induces both apoptosis and autophagy in HCC cells through the AMPK-mTOR signaling cascade, plays a role in cancer suppression and has therapeutic implications for HCC patients.

3.1. Histone Modification. Histone modifications, as a class of epigenetic regulatory mechanisms that regulate gene expression, have received increasing attention because their modification pattern changes are closely related to the development of a variety of malignancies [92]. For example, cell differentiation and organismal development and abnormal modifications of histones contribute to diseases such as cancer [93]. Zhang et al. [94] found that acetazolamide (SIRT1), a NAD+-dependent histone deacetylase, exerts antioncogenic effects in HCC through the AMPK-mTOR pathway in the context of mutant p53. Wang et al. [95] found that inhibition of histone methyltransferase 3 (SMYD3) resulted in reduced AKT/mTOR signaling activity, which triggered deleterious effects on bladder cancer cells. In addition, Makarević et al. [96] found that decreased acetylation of H3 and H4 promotes prostate cancer cell development by activating the mTOR signaling pathway in prostate cancer. Sun et al. [97] found that inhibition of mTOR signaling enhanced trichostatin A and promoted histone acetylation in gastric cancer cell lines. To date, there have been no reports on the role of histone methylation and acetylation in liver cancer through the mTOR signaling pathway.

4. Chromatin Remodeling

The SWI/SNF complex, originally discovered in yeast 20 years ago, is a family of multi-subunit complexes that use the energy of ATP hydrolysis to remodel nucleosomes. Chromatin remodeling processes mediated by the SWI/SNF complex are essential for the regulation of gene expression in a variety of cellular processes, including differentiation and proliferation [98]. Many studies have found that the chromatin SWI/SNF complex plays an important role in malignant tumors. Zhou and his team [99] discovered SMARCD1, a subunit of the SWI/SNF complex, as a promising prognostic predictor that promotes liver cancer growth through the mTOR pathway.

5. Conclusions and Perspectives

Multiple studies have demonstrated that epigenetic changes play an important role in the development and progression of HCC. The mTOR pathway is involved in the growth and proliferation of HCC cells, and epigenetic regulation through mTOR signaling will affect HCC progression. As supported by increasing evidence, epigenetic regulators through the mTOR signaling pathway as ideal therapeutic targets for HCC are a potent future research direction. Although there have been major breakthroughs in epigenetics in the treatment of HCC, some questions remain unanswered. For example, studies linking histone methylation and acetylation with the mTOR signaling pathway are scarce. Future studies should pursue this research direction to expand the exploration of strategies for HCC treatment targeting the mTOR pathway.

Table 2: Dysregulated lncRNAs in HCC.

<table>
<thead>
<tr>
<th>LncRNA</th>
<th>Target</th>
<th>Expression</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li et al.</td>
<td>LncRNA DCST1-AS1</td>
<td>mTOR pathway</td>
<td>Upregulated</td>
</tr>
<tr>
<td>Chen et al.</td>
<td>LncRNA OGFRP1</td>
<td>mTOR pathway</td>
<td>Upregulated</td>
</tr>
<tr>
<td>Guo et al.</td>
<td>LncRNA TMPO-AS1</td>
<td>FOXK1</td>
<td>Upregulated</td>
</tr>
<tr>
<td>Peng et al.</td>
<td>LncRNA MALAT1</td>
<td>PI3K3' noncoding region</td>
<td>Upregulated</td>
</tr>
<tr>
<td>Malaker et al.</td>
<td>LncRNA MALAT1</td>
<td>TCF7L2</td>
<td>Upregulated</td>
</tr>
<tr>
<td>Ye et al.</td>
<td>LncRNA AK023948</td>
<td>mTOR pathway</td>
<td>Upregulated</td>
</tr>
<tr>
<td>Wei et al.</td>
<td>LncRNA HAGLROS</td>
<td>MiR-5059/AGLROS axis</td>
<td>Upregulated</td>
</tr>
<tr>
<td>Zheng et al.</td>
<td>LncRNA CDKN2B-AS1</td>
<td>Let-7c-5p/NAP1L1 axis</td>
<td>Upregulated</td>
</tr>
<tr>
<td>Zhong et al.</td>
<td>LncRNA SNHG16</td>
<td>p62</td>
<td>Upregulated</td>
</tr>
<tr>
<td>Han et al.</td>
<td>LncRNA CASC11</td>
<td>PTEN</td>
<td>Upregulated</td>
</tr>
<tr>
<td>Sun et al.</td>
<td>LncRNA DUXAP10</td>
<td>GRP39</td>
<td>Upregulated</td>
</tr>
<tr>
<td>Liu et al.</td>
<td>LncRNA PICSAR</td>
<td>MiR-588</td>
<td>Upregulated</td>
</tr>
<tr>
<td>Shu et al.</td>
<td>LncRNA LINC00680</td>
<td>AKT3</td>
<td>Upregulated</td>
</tr>
<tr>
<td>Xin et al.</td>
<td>LncRNA HULC</td>
<td>PTEN</td>
<td>Downregulated</td>
</tr>
</tbody>
</table>

Data Availability

The data used to support this study are included within this article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

All authors made substantial contributions to acquisition of data, or analysis, conception and design, and interpretation of data; took part in drafting of the article or revising it critically for important intellectual content; gave final
Acknowledgments

The authors thank Gabrielle White Wolf, Ph.D., from Liwen Bianji, Edanz Editing China (http://www.liwenbianji.cn), for editing the English text of a draft of this manuscript. This study was supported by grants from the Natural Science Foundation of Hebei Province (grant no. H2019209355), the Science and Technology Research Project of Hebei Higher Education Institutions (grant no. ZD2018090), the Hebei Provincial Health Commission Office (grant no. G2019074), the Hebei Science and Technology Research Project of Hebei Higher Education Institutions (grant no. ZD2018090), and Project of Hebei Provincial Department of Education (grant no. KCJSZ2020056).

References


[69] Y. Han, M. Chen, A. Wang, and X. Fan, "STAT3-induced upregulation of lncRNA CASCI1 promotes the cell migration, invasion and epithelial-mesenchymal transition in hepatocellular carcinoma by epigenetically silencing PTEN and activating PI3K/AKT signaling pathway," *Biochemical and Biophysical Research Communications*, vol. 508, no. 2, pp. 472–479, 2019.


[80] Y. Zhao, "Deficiency in the ubiquitin conjugating enzyme UBE2A in Alzheimer’s disease (AD) is linked to deficits in a natural circular miRNA-7 sponge (circRNA: ciRS-7)," *Genes (Basel)*, vol. 7, no. 12, 2016.


